{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:30:32Z","timestamp":1747204232154,"version":"3.40.5"},"posted":{"date-parts":[[2022,8,5]]},"group-title":"In Review","reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,7,3]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background<\/bold>: Since August 2021, multiple vaccines have been approved to prevent infection with SARS-CoV-2; however, 20-40 % of immunocompromised people fail to develop SARS-CoV-2 spike antibodies after COVID-19 vaccination and remain at an exceptionally high risk of infection and more severe illness than non-immunocompromised hosts. Sotrovimab (VIR-7831) is an engineered monoclonal antibody that targets a highly conserved epitope on the SARS-CoV-2 spike glycoprotein. It is neither renally excreted nor metabolized by P450 (CYP) enzymes; therefore, interactions with concomitant medications are unlikely, which is an important consideration for patients receiving multiple immunosuppressive medications. In this Phase II open-label safety and tolerability study protocol, we propose to evaluate the safety and tolerability of sotrovimab as pre-exposure prophylaxis for immunocompromised individuals.<bold>Methods<\/bold>: We will enroll a total of 93 eligible immunocompromised adults with a negative or low-positive (&lt;50 U\/mL) SARS-CoV-2 spike antibody. In Phase 1, the first 10 patients will participate in a lead-in pharmacokinetics (PK) cohort study to determine the optimal dosing interval between two sequential doses of sotrovimab. Phase 2 will expand this population to 50 participants to examine rates of infusion-related reactions (IRR) with a 30-minute 500mg sotrovimab IV infusion. Phase 3 will be an expansion cohort for further assessment of the safety and tolerability of sotrovimab in this patient population. In Phase 4, the first 10 patients receiving 2000mg IV of sotrovimab on the second sotrovimab infusion day (Treatment Day 2) will comprise a lead-in safety cohort that will inform the duration of observation following administration of the drug, with the observation period being reduced from two hours to one hour for the remaining study population if none of these patients have a grade 3-4 infusion-related reaction. The patients will be followed for safety and COVID-19 events for an additional 36 weeks after the second dose.<bold>Discussion<\/bold>: In a previous Phase III randomized, placebo-controlled pivotal trial, there were no significant differences in the prevalence of adverse events in patients receiving  sotrovimab vs. placebo. Thus, we propose to study the safety and tolerability of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection and evaluate its PK in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity. We also aim to determine COVID-19 infections over the study period and self-reported quality of life measures over the course of the study.<bold>Trial registration<\/bold>: ClinicalTrials.gov Identifier: NCT05210101<\/p>","DOI":"10.21203\/rs.3.rs-1821159\/v1","type":"posted-content","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T23:41:17Z","timestamp":1659742877000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals with Impaired SARS-CoV-2 Humoral Immunity"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-092X","authenticated-orcid":false,"given":"Isabel H","family":"Gonzalez-Bocco","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Beluch","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Cho","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian M","family":"Unger-Mochrie","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Lahoud","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola A","family":"Reyes","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios G","family":"Moshovitis","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah P","family":"Hammond","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Manne-Goehler","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe Covid-19","volume":"385","author":"Berlin DA","year":"2020","unstructured":"Berlin DA, Gulick RM, Martinez F. Severe Covid-19. N Engl J Med. 2020;385:2451\u201360.","journal-title":"N Engl J Med"},{"year":"2021","author":"Research US","key":"ref2","unstructured":"Center for Drug Evaluation and. Research US Food and Drug Administration. Coronavirus (COVID-19): Drugs. 2021."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host","volume":"383","author":"Choi B","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383:2291\u20133.","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"U.S. Food and Drug Administration. Covid-19 vaccines.. 2021."},{"key":"ref5","unstructured":"Covid Data Tracker Weekly Review. Centers for Disease Control and Prevention. 2021."},{"year":"2021","author":"Comirnaty","key":"ref6","unstructured":"Comirnaty. \\U.S. Food and Drug Administration. 2021."},{"issue":"25","key":"ref7","first-page":"2881","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"17","author":"Vijenthira A","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020 Dec 17;136(25):2881\u201392.","journal-title":"Blood. 2020 Dec"},{"key":"ref8","unstructured":"Severe outcomes among patients. with coronavirus disease 2019 (COVID-19). Centers for Disease Control and Prevention. 2020."},{"key":"ref9","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients","volume":"7","author":"Agha M","year":"2021","unstructured":"Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv. 2021 Apr 7.","journal-title":"medRxiv"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar A","year":"2021","unstructured":"Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081\u201390.e2.","journal-title":"Cancer Cell"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"10","author":"Malard F","year":"2021","unstructured":"Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer Journal. 2021 Aug;10(8):142. 11(.","journal-title":"Blood Cancer Journal"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo A","year":"2021","unstructured":"Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, di Marco M, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091\u20138.e2.","journal-title":"Cancer Cell"},{"issue":"23","key":"ref13","first-page":"3165","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"10","author":"Herishanu Y","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021 Jun 10;137(23):3165\u201373.","journal-title":"Blood. 2021 Jun"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger LM","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031\u20133.","journal-title":"Cancer Cell"},{"year":"2021","author":"Ollila TA","key":"ref15","unstructured":"Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, et al. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA Oncology. 2021 Nov 1;7(11):1714."},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis K","year":"2021","unstructured":"Maneikis K, \u0160ablauskas K, Ringelevi\u010di\u016bt\u0117 U, Vaitek\u0117nait\u0117 V, \u010cekauskien\u0117 R, Kry\u017eauskait\u0117 L, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021 Aug;8(8):e583\u201392.","journal-title":"Lancet Haematol"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","article-title":"Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer","volume":"39","author":"Mairhofer M","year":"2021","unstructured":"Mairhofer M, Kausche L, Kaltenbrunner S, Ghanem R, Stegemann M, Klein K, et al. Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer. Cancer Cell. 2021;39(9):1171\u20132.","journal-title":"Cancer Cell"},{"issue":"9","key":"ref18","first-page":"1330","article-title":"Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine","volume":"174","author":"Werbel WA","year":"2021","unstructured":"Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Annals of Internal Medicine. 2021 Sep;174(9):1330\u20132."},{"author":"Kamar N","key":"ref19","unstructured":"Kamar N, Abravanel F, Marion O, Couat C, Izopet J, del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine. 2021 Aug 12;385(7):661\u20132."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression","volume":"385","author":"Corey L","year":"2021","unstructured":"Corey L, Beyrer C, Cohen MS. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385:562\u20136.","journal-title":"N Engl J Med"},{"issue":"9","key":"ref21","first-page":"1332","article-title":"Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series. Annals of Internal Medicine","volume":"174","author":"Connolly CM","year":"2021","unstructured":"Connolly CM, Boyarsky BJ, Ruddy JA, Werbel WA, Christopher-Stine L, Garonzik-Wang JM, et al. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series. Annals of Internal Medicine. 2021 Sep;174(9):1332\u20134."},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response","volume":"80","author":"Bonelli MM","year":"2021","unstructured":"Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. Annals of the Rheumatic Diseases. 2021 Oct;80(10):1355\u20136.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin D","year":"2021","unstructured":"Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021 Sep;148(3):739\u201349.","journal-title":"J Allergy Clin Immunol"},{"key":"ref24","volume-title":"associated with higher risk for severe COVID-19: Information for Healthcare Providers","author":"Underlying medical conditions","year":"2021","unstructured":"Underlying medical conditions. associated with higher risk for severe COVID-19: Information for Healthcare Providers. Centers for Disease Control and Prevention; 2021."},{"issue":"1","key":"ref25","article-title":"Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)","volume":"12","author":"Kampen JJ","year":"2021","unstructured":"van Kampen JJ, van de Vijver DA, Fraaij PL. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nature Communications. 2021;12(1).","journal-title":"Nature Communications"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12934-021-01576-5","article-title":"Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment","volume":"22","author":"Valdez-Cruz NA","year":"2021","unstructured":"Valdez-Cruz NA, Garc\u00eda-Hern\u00e1ndez E, Espitia C, Cobos-Mar\u00edn L, Altamirano C, Bando-Campos CG, et al. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microb Cell Fact. 2021 Dec;22(1):88. 20(.","journal-title":"Microb Cell Fact"},{"key":"ref27","unstructured":"Fact Sheet for Healthcare. Providers Emergency Use Authorization (EUA) of Sotrovimab.. GlaxoSmithKline."},{"issue":"21","key":"ref28","first-page":"1941","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"18","author":"Gupta A","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New England Journal of Medicine. 2021 Nov 18;385(21):1941\u201350.","journal-title":"New England Journal of Medicine. 2021 Nov"},{"key":"ref29","volume-title":"Corrected Version 2.1","author":"Division of AIDS (DAIDS)","year":"2017","unstructured":"Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events. In: Corrected Version 2.1. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS; 2017."},{"key":"ref30","volume-title":"Summary binx health At-home Nasal Swab COVID-19 Sample Collection Kit","author":"Emergency Use Authorization (EUA)","year":"2021","unstructured":"Emergency Use Authorization (EUA). Summary binx health At-home Nasal Swab COVID-19 Sample Collection Kit. U.S. Food and Drug Administration.; 2021."},{"key":"ref31","volume-title":"19 Sample Collection Kit \u2013 for Individual Shipping, Instructions for Use","author":"binx health At-home Nasal Swab COVID-","year":"2021","unstructured":"binx health At-home Nasal Swab COVID-. 19 Sample Collection Kit \u2013 for Individual Shipping, Instructions for Use. U.S. Food and Drug Administration; 2021."},{"key":"ref32","unstructured":"Symptoms of COVID-19. Centers for Disease Control and Prevention. 2021."},{"key":"ref33","article-title":"Short Form Survey (SF-36)","author":"36-Item","year":"2021","unstructured":"36-Item. Short Form Survey (SF-36). RAND Corporation. 2021.","journal-title":"RAND Corporation"},{"issue":"7870","key":"ref34","first-page":"103","article-title":"In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","volume":"5","author":"Chen RE","unstructured":"Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021 Aug 5;596(7870):103\u20138.","journal-title":"Nature. 2021 Aug"},{"issue":"6","key":"ref35","first-page":"1517","article-title":"Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice","volume":"15","author":"Baxter LT","unstructured":"Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994 Mar 15;54(6):1517\u201328.","journal-title":"Cancer Res. 1994 Mar"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1124\/dmd.119.086488","article-title":"Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides","volume":"47","author":"Datta-Mannan A","year":"2019","unstructured":"Datta-Mannan A. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. Drug Metab Dispos. 2019 Oct;47(10):1100\u201310.","journal-title":"Drug Metab Dispos"},{"year":"2021","author":"Rozen-Zvi B","key":"ref37","unstructured":"Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clinical Microbiology and Infection. 2021 Aug;27(8):1173.e1-1173.e4."},{"issue":"13","key":"ref38","first-page":"1244","article-title":"Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients","volume":"23","author":"Hall VG","unstructured":"Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. New England Journal of Medicine. 2021 Sep 23;385(13):1244\u20136.","journal-title":"New England Journal of Medicine. 2021 Sep"},{"year":"2020","author":"Huang Y","key":"ref39","unstructured":"Huang Y, Yang C, Xu X, feng, Xu W, Liu S wen. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica. 2020 Sep 3;41(9):1141\u20139."},{"issue":"7857","key":"ref40","first-page":"130","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature","volume":"6","author":"Wang P","year":"2021","unstructured":"Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 May 6;593(7857):130\u20135."},{"key":"ref41","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2","author":"Cathcart AL","year":"2021","unstructured":"Cathcart AL, Nair MS, Liu L. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021;(03.09.434607).","journal-title":"bioRxiv"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti D","year":"2021","unstructured":"Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021 Jun;184(12):3086\u2013108.","journal-title":"Cell"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cpt.2420","article-title":"Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection","volume":"110","author":"Chigutsa E","year":"2021","unstructured":"Chigutsa E, O\u2019Brien L, Ferguson-Sells L, Long A, Chien J. Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID-19 Infection. Clin Pharmacol Ther. 2021;110(5):1302\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/cpt.2459","article-title":"A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial","volume":"111","author":"Chigutsa E","year":"2022","unstructured":"Chigutsa E, Jordie E, Riggs M, Nirula A, Elmokadem A, Knab T, et al. A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti-SARS-CoV-2 Monoclonal Antibodies to Advance Bamlanivimab Into a First-in-Human Clinical Trial. Clin Pharmacol Ther. 2022;111(3):595\u2013604.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.xphs.2017.03.033","article-title":"Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis","volume":"106","author":"Jadhav SB","year":"2017","unstructured":"Jadhav SB, Khaowroongrueng V, Fueth M, Otteneder MB, Richter W, Derendorf H. Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis. J Pharm Sci. 2017;106(9):2853\u20139.","journal-title":"J Pharm Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones BE","year":"2021","unstructured":"Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13:593.","journal-title":"Sci Transl Med"},{"issue":"8","key":"ref47","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00350-19","article-title":"Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers","volume":"63","author":"Magyarics Z","year":"2019","unstructured":"Magyarics Z, Leslie F, Bartko J, Rouha H, Luperchio S, Sch\u00f6rgenhofer C, et al. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. Antimicrob Agents Chemother. 2019;63(8).","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref48","first-page":"297","article-title":"Antibody biodistribution coefficients. MAbs","volume":"27","author":"Shah DK","year":"2013","unstructured":"Shah DK, Betts AM. Antibody biodistribution coefficients. MAbs. 2013 Mar 27;5(2):297\u2013305."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-1821159\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-1821159\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:47:32Z","timestamp":1697514452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-1821159\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":48,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-1821159\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s40814-023-01325-y","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2022,8,5]]},"subtype":"preprint"}}